Nitric oxide from mononuclear cells may be involved in platelet responsiveness to aspirin

Eur J Clin Invest. 2014 May;44(5):463-9. doi: 10.1111/eci.12252.

Abstract

Background: Several mechanisms have been proposed to explain why some platelets have a reduced response to aspirin (ASA). Among them, it was reported an increased circulating level of vitamin-D-binding protein (DBP). In addition, nitric oxide (NO) released from mononuclear cells was involved in the antiplatelet effects of ASA. The aim was to analyse the relationship between platelet response to ASA and both NO generation and vitamin-D-binding protein content in mononuclear cells.

Materials and methods: Mononuclear cells were obtained from patients with stable coronary artery disease that were divided by a platelet functionality test (PFA-100) as ASA-sensitive (n=23) and ASA resistant (n=27).

Results: Both the release of NO (determined by nitrite+nitrate concentration) and the expression of endothelial-type NO synthase (eNOS) were higher in mononuclear cells from ASA sensitive as compared with those from ASA-resistant patients. There was a positive correlation between either the release of NO and the expression of eNOS protein in mononuclear cells with the ability of ASA to inhibit platelet activity. DBP content in mononuclear cells was higher in ASA resistant than in ASA sensitive. The level of DBP content in mononuclear cells was negatively associated with the ability of ASA to inhibit platelets. However, in vitro experiments suggested that there was no association between DBP and NO production by mononuclear cells.

Conclusions: Mononuclear cells from patients with platelets with lower responsiveness to ASA showed a reduced ability to produce NO.

Keywords: Aspirin; mononuclear cells; nitric oxide; platelets; vitamin-D-binding protein.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Aspirin / pharmacology*
  • Blood Platelets
  • Coronary Artery Disease / drug therapy
  • Coronary Artery Disease / metabolism
  • Drug Resistance
  • Female
  • Humans
  • Interleukin-6 / biosynthesis
  • Leukocytes, Mononuclear / metabolism
  • Male
  • Nitric Oxide / biosynthesis*
  • Nitric Oxide Synthase Type II / metabolism
  • Nitric Oxide Synthase Type III / metabolism
  • Platelet Aggregation Inhibitors / pharmacology*
  • Vitamin D-Binding Protein / metabolism

Substances

  • Interleukin-6
  • Platelet Aggregation Inhibitors
  • Vitamin D-Binding Protein
  • Nitric Oxide
  • Nitric Oxide Synthase Type II
  • Nitric Oxide Synthase Type III
  • Aspirin